Chip design software, verification and IP. TickerStar monitors official filings, investor releases, earnings, and call updates for Synopsys. Subscribe to SNPS alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.
TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.
SNPS beat prior Q2 FY2026 Non-GAAP EPS guidance by +$0.21. Q2 revenue increased 41.9% year-over-year driven by the Ansys acquisition and strong business performance, while non-GAAP operating margin expanded to 28.3%. For Q3 FY2026, revenue guidance is $2,410 million-$2,460 million (midpoint $2,435 million) and non-GAAP EPS guidance is $3.63-$3.69 (midpoint $3.66).
Subscribe to read moreSNPS filed its 10-Q; the most relevant disclosure change is expanded Business combinations: Ansys acquisition completed July 17, 2025 for $34.9 billion; purchase price allocated to tangible and identified intangible assets based on preliminary estimated fair values; measurement period adjustments ongoing.
Subscribe to read moreSNPS filed its 10-Q; the most relevant disclosure change is expanded Business combinations: Ansys acquisition closed July 17, 2025 for $34.9 billion total consideration ($17.6 billion cash, $17.1 billion Synopsys stock). Ansys contributed $886 million in Q1 FY2026 revenue.
Subscribe to read moreSynopsys, Inc. filed a Schedule 14A Definitive Additional Materials (DEFA14A) on February 19, 2026, in connection with a proxy solicitation. The filing indicates no fee was required for this submission. The document contains minimal substantive content beyond the standard cover page, with 929 characters of clean text indicating this is supplemental proxy-related disclosure rather than a full proxy statement or annual report with detailed voting items or financial guidance.
Subscribe to read moreSynopsys filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for April 16, 2026. The proxy includes ten director nominees, an advisory vote on executive compensation, approval of an amended equity incentive plan to include non-employee directors, and ratification of KPMG LLP as auditor. Fiscal 2025 results showed record revenue of $7.054 billion, up approximately 15% year-over-year, with GAAP operating margin of 13.0% and non-GAAP operating margin of 37.3%.
Subscribe to read moreSNPS filed its 10-K; the most relevant disclosure change is expanded Business combinations: Ansys acquisition completed July 17, 2025 for $34.9 billion total consideration including $17.6 billion cash and $17.1 billion in Synopsys stock. Goodwill of $23.5 billion recorded. Intangible assets of $13.0 billion including developed technology ($6.5 billio. Customer concentration: One customer (Customer A) represented 12.6% of revenue.
Subscribe to read moreSynopsys, Inc. filed a Form D notice on December 8, 2025, for a new exempt offering of equity securities under Rule 506(b), with a first sale occurring on December 1, 2025. The offering amount is approximately $2 billion, with the entire amount reported as sold to a single investor who made a minimum investment of approximately $2 billion. No sales commissions or finders' fees were paid, and no proceeds were allocated to payments to executive officers or directors.
Subscribe to read moreSynopsys announced that Rick Mahoney has departed as Chief Revenue Officer, effective immediately, with the company stating it is in advanced stages of searching for a replacement. The company reaffirmed its financial targets for Q4 FY2025 and full fiscal year 2025, and will discuss results at its earnings call on December 10, 2025. The filing does not contain actual financial results.
Subscribe to read moreSNPS miss prior Q3 FY2025 Non-GAAP EPS (diluted) guidance by $-0.46. Revenue of $1.740 billion grew 14% year-over-year, driven by Design Automation (+23.5% YoY to $1.312 billion), partially offset by Design IP weakness (-7.7% YoY to $427.6 million). For Q4 FY2025, Revenue guidance is $2,230 million-$2,260 million (midpoint $2,245 million) and Non-GAAP EPS guidance is $2.76-$2.80 (midpoint $2.78).
Subscribe to read moreSNPS filed its 10-Q; the most relevant disclosure change is added Business combinations - Ansys acquisition: Completed acquisition of Ansys for total consideration of $34.9 billion on July 17, 2025; preliminary allocation includes goodwill of $23.5 billion, intangibles of $13.0 billion (core technology $6.5 billion, customer relationships $5.1 billion, trademarks $95. Customer concentration: Major customers represented 68.6% (EDA), 24.6% (Design IP), 4.5% (S&A) of revenue.
Subscribe to read moreSynopsys, Inc. filed a Form S-8 registration statement on July 23, 2025 to register up to 1,132,822 shares of its common stock issuable under three ANSYS, Inc. equity compensation plans following the completion of the ANSYS merger on July 17, 2025. The registration covers assumed restricted stock units, performance stock units, and stock options from ANSYS's 2021 Equity and Incentive Compensation Plan and two amended and restated 1996 stock option plans.
Subscribe to read moreSynopsys, Inc. completed its acquisition of Ansys, Inc. on July 17, 2025, pursuant to the Agreement and Plan of Merger dated January 15, 2024. At the effective time, each Ansys share was converted into 0.3399 shares of Synopsys common stock plus $199.91 in cash, subject to Exchange Ratio adjustment due to the Maximum Share Number limitation. The acquisition was financed through $10.0 billion in senior notes issued March 17, 2025, $4.3 billion borrowed under the Term Loan Credit Agreement on July 17, 2025, and ca...
Subscribe to read moreSynopsys has suspended its financial guidance for the third quarter of fiscal year 2025 and full fiscal year 2025 following receipt of a letter from the Bureau of Industry and Security of the U.S. Department of Commerce informing the company of new export restrictions related to China. The company is currently assessing the potential impact of the BIS Letter on its business, operating results, and financial condition.
Subscribe to read moreSynopsys, Inc. filed an S-8 registration statement to register 1,600,000 additional shares issuable under its 2006 Employee Equity Incentive Plan and 2,200,000 additional shares issuable under its Employee Stock Purchase Plan, totaling 3,800,000 additional shares of common stock for employee equity compensation purposes.
Subscribe to read moreSNPS beat prior Q2 FY2025 Non-GAAP EPS (diluted) guidance by +$0.27. Revenue of $1.604 billion exceeded guidance, and the company reaffirmed full-year 2025 revenue guidance of $6.745-$6.805 billion and non-GAAP operating margin guidance while issuing Q3 FY2025 targets. For Q3 FY2025 (ending July 31, 2025), Revenue guidance is $1,755 million-$1,785 million (midpoint $1,770 million) and Non-GAAP EPS guidance is $3.82-$3.87 (midpoint $3.85).
Subscribe to read moreSNPS filed its 10-Q; the most relevant disclosure change is added Senior Notes issued: Issued $10 billion in senior notes in March 2025 with net proceeds of $9.9 billion to fund Ansys merger.
Subscribe to read moreSynopsys, Inc. filed a prospectus supplement for an offering of six series of senior notes with aggregate principal amounts, interest rates, and maturity dates to be determined at pricing. The company intends to use the net proceeds, along with cash on hand and borrowings under the Term Loan Credit Agreement and Bridge Commitment, to fund the approximately $35.0 billion cash-and-stock acquisition of ANSYS, Inc., pay related transaction fees and expenses, and repay Ansys' outstanding indebtedness. The offering is...
Subscribe to read moreSynopsys reported Q1 FY2025 revenue of $1.455 billion, which was at the midpoint of the company's guided range, while non-GAAP EPS of $3.03 exceeded guidance. Revenue declined 3.7% year-over-year due to the sale of the Software Integrity business and a 53-week fiscal year effect in the prior year period, with Design IP segment revenue declining 17.2% to $435.1 million. The company reaffirmed its full-year 2025 guidance including revenue of $6.745-$6.805 billion and non-GAAP EPS of $14.88-$14.96. For Q2 FY2025 (T...
Subscribe to read moreSNPS filed its 10-Q; the most relevant disclosure change is changed Fiscal year-end change: Fiscal year end changed from Saturday nearest October 31 to fixed October 31 each year, effective FY2025 beginning November 3, 2024; quarters now end January 31, April 30, July 31, October 31.
Subscribe to read moreSynopsys, Inc. has filed its definitive proxy statement for the 2025 Annual Meeting of Stockholders scheduled for April 10, 2025 at 8:00 AM PT via virtual webcast. The proxy includes nine director nominees for election, proposals to increase shares available under the 2006 Employee Equity Incentive Plan by 1,600,000 shares and under the Employee Stock Purchase Plan by 2,200,000 shares, an advisory say-on-pay vote, ratification of KPMG LLP as independent auditor, and a stockholder proposal regarding shareholder r...
Subscribe to read more